2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

SESSION

602. Myeloid Oncogenesis: Basic: Poster I

Program: Poster Abstract Session
Saturday, December 12, 2026
05:30 p.m. - 07:30 p.m.
MCCNO - Hall F
Technology and Procedures, Assays, Molecular Testing, Omics Technologies, Pathology, Bioinformatics, Cell Expansion, Gene Editing, Profiling, Treatment Considerations, Combination Therapy, Biological Therapies, Antibody Therapy, Biological Processes, Apoptosis, Pathogenesis, CHIP, Genomics, Hematopoiesis, Immune Mechanism, Metabolism, Molecular Biology, Diseases, Genetic Disorders, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, Research, Fundamental Science, AML, Translational Research, MDS, CMML, Study Population, Human, Adult, Animal Model
PAPER

1444 Loss of PLK2 promotes acute myeloid leukemia progression through aberrant CBL splicing and sustained CSF1R signaling

Hanyu Wang, PhD, Jing Zhou2, Meijuan Huang3, Ying Liu4, Jia Wu5, Lingfeng Zhang6, Yang Cao, MD7, Liang Huang, MD8, Dengju Li, MD9, Jia Wei, MD, PhD10, Jue Wang11
1 Department of Hematology, Tongji Hospital, Tongji Medical College Huazhong University of Science and Technology, Wuhan, China, Wuhan, China
2 Department of Hematology, Tongji Hospital, Tongji Medical College Huazhong University of Science and Technology, Wuhan, China, Wuhan, China
3 Department of Hematology, Tongji Hospital, Tongji Medical College Huazhong University of Science and Technology, Wuhan, China, Wuhan, China
4 Department of Hematology, Tongji Hospital, Tongji Medical College Huazhong University of Science and Technology, Wuhan, China, Wuhan, China
5 Department of Hematology, Tongji Hospital, Tongji Medical College Huazhong University of Science and Technology, Wuhan, China, Wuhan, China
6 Department of Hematology, Tongji Hospital, Tongji Medical College Huazhong University of Science and Technology, Wuhan, China, Wuhan, China
7 Department of Hematology, Tongji Hospital, Tongji Medical College Huazhong University of Science and Technology, Wuhan, China, Wuhan, China
8 Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Wuhan, China
9 Department of Hematology, Tongji Hospital, Tongji Medical College Huazhong University of Science and Technology, Wuhan, China, Wuhan, China
10 Department of Hematology, Tongji Hospital, Tongji Medical College Huazhong University of Science and Technology, Wuhan, China, Wuhan, China
11 Department of Hematology, Tongji Hospital, Tongji Medical College Huazhong University of Science and Technology, Wuhan, China, Wuhan, China

Objective:
Although PLK2 has been implicated in cancer biology, its function in hematopoiesis and acute myeloid leukemia (AML) remains poorly defined. Here, we investigated how PLK2 regulates leukemic stem/progenitor cell function and AML progression.

Methods:
We examined PLK2 expression and clinical correlates using public datasets and patient samples. To define the physiological role of PLK2, we generated hematopoietic-specific (Vav-Cre) and myeloid-specific (Lyz2-Cre) Plk2 conditional knockout mice, followed by peripheral blood analysis, bone marrow evaluation, flow cytometry, and competitive transplantation assays. An MLL-AF9-driven AML model was subsequently used to determine the impact of Plk2 loss on leukemogenesis. Mechanistically, we integrated phosphoproteomic and transcriptomic profiling with alternative splicing analysis (rMATS), and validated the PLK2-SRSF1-CBL-CSF1R axis using molecular and biochemical approaches.

Results:
PLK2 was upregulated in AML patients and associated with MLL rearrangements, complex karyotype, and chemoresistance. Plk2 deletion did not affect steady-state multilineage hematopoiesis or HSC maintenance; however, competitive transplantation revealed enhanced myeloid repopulation following Plk2 loss. In the MLL-AF9 model, Plk2 deficiency accelerated disease progression, shortened survival, and expanded leukemic stem/progenitor populations. Mechanistically, PLK2 loss reduced SRSF1 RS-domain phosphorylation and altered SRSF1 subcellular localization, weakening its interaction with Cbl pre-mRNA and promoting exon 8+9 skipping. The resulting Cbl ΔE8+9 isoform impaired CBL-mediated CSF1R ubiquitination and degradation, increasing CSF1R stability. CSF1 stimulation induced sustained activation of downstream PI3K-AKT/mTOR and MAPK-ERK signaling. Clinical dataset analyses further supported the relevance of this regulatory axis in AML.

Conclusions:
Our findings establish PLK2 as a tumor suppressor in AML. Notably, PLK2 is largely dispensable for normal hematopoiesis. PLK2 loss promotes aberrant CBL splicing through SRSF1 dysregulation, resulting in impaired CSF1R turnover and persistent oncogenic signaling. The PLK2-SRSF1-CBL-CSF1R axis represents a potential therapeutic vulnerability in AML.

Hanyu Wang, PhD: No relevant conflicts of interest to declare.